SE9904413D0 - Comminuted form - Google Patents

Comminuted form

Info

Publication number
SE9904413D0
SE9904413D0 SE9904413A SE9904413A SE9904413D0 SE 9904413 D0 SE9904413 D0 SE 9904413D0 SE 9904413 A SE9904413 A SE 9904413A SE 9904413 A SE9904413 A SE 9904413A SE 9904413 D0 SE9904413 D0 SE 9904413D0
Authority
SE
Sweden
Prior art keywords
compound
pharmaceutically acceptable
particle size
acceptable salt
reduced particle
Prior art date
Application number
SE9904413A
Other languages
English (en)
Swedish (sv)
Inventor
Kristina Roos
Agneta Haellgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904413A priority Critical patent/SE9904413D0/xx
Publication of SE9904413D0 publication Critical patent/SE9904413D0/xx
Priority to DK00983616T priority patent/DK1237854T3/da
Priority to SI200030251T priority patent/SI1237854T1/xx
Priority to BR0016135-7A priority patent/BR0016135A/pt
Priority to PT00983616T priority patent/PT1237854E/pt
Priority to UA2002053989A priority patent/UA73959C2/uk
Priority to PL00355372A priority patent/PL355372A1/xx
Priority to IL14951600A priority patent/IL149516A0/xx
Priority to SK766-2002A priority patent/SK7662002A3/sk
Priority to AT00983616T priority patent/ATE251131T1/de
Priority to CN008163839A priority patent/CN1216859C/zh
Priority to HU0203692A priority patent/HUP0203692A3/hu
Priority to CZ20021839A priority patent/CZ20021839A3/cs
Priority to JP2001541856A priority patent/JP2003515580A/ja
Priority to EP00983616A priority patent/EP1237854B1/en
Priority to KR1020027007058A priority patent/KR20020067538A/ko
Priority to RU2002113169/04A priority patent/RU2248966C2/ru
Priority to DE60005710T priority patent/DE60005710T2/de
Priority to PCT/SE2000/002381 priority patent/WO2001040169A1/en
Priority to MXPA02005165A priority patent/MXPA02005165A/es
Priority to NZ518926A priority patent/NZ518926A/en
Priority to AU20348/01A priority patent/AU766036B2/en
Priority to ES00983616T priority patent/ES2208444T3/es
Priority to US10/148,825 priority patent/US7084177B2/en
Priority to TR2004/00003T priority patent/TR200400003T4/xx
Priority to EEP200200284A priority patent/EE200200284A/xx
Priority to CA002392029A priority patent/CA2392029A1/en
Priority to CO00091759A priority patent/CO5271736A1/es
Priority to MYPI20005601A priority patent/MY125099A/en
Priority to ARP000106384A priority patent/AR029456A1/es
Priority to ZA200203797A priority patent/ZA200203797B/en
Priority to IS6399A priority patent/IS6399A/is
Priority to NO20022591A priority patent/NO20022591L/no
Priority to HK03101434.9A priority patent/HK1049324B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9904413A 1999-12-03 1999-12-03 Comminuted form SE9904413D0 (sv)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form
CA002392029A CA2392029A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
RU2002113169/04A RU2248966C2 (ru) 1999-12-03 2000-11-29 Измельченная форма (s)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты
PCT/SE2000/002381 WO2001040169A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
BR0016135-7A BR0016135A (pt) 1999-12-03 2000-11-29 Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto
DE60005710T DE60005710T2 (de) 1999-12-03 2000-11-29 Feinteilige form von (s)-2-ethoxy -3- 4-(2- 4-methansulfonyloxyphenyl ethoxy)phenyl]propansäure
UA2002053989A UA73959C2 (en) 1999-12-03 2000-11-29 Grinded form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy]phenyl)]propane acid, a method for the preparation thereof and a pharmaceutical composition
PL00355372A PL355372A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
IL14951600A IL149516A0 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
SI200030251T SI1237854T1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl) propanoic acid
AT00983616T ATE251131T1 (de) 1999-12-03 2000-11-29 Feinteilige form von (s)-2-ethoxy -3- 4-(2- 4- methansulfonyloxyphenyl ethoxy)phenyl)propansäure
CN008163839A CN1216859C (zh) 1999-12-03 2000-11-29 (s)－2－乙氧基－3－[4－(2－{4－甲磺酰基氧基苯基}乙氧基)苯基]丙酸的粉碎形式
HU0203692A HUP0203692A3 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy-3-{4-[2-(4-/methanesulfonyloxy/-phenyl)-ethoxy]-phenyl}-propanoic acid and pharmaceutical compoisitions containing them and their use
CZ20021839A CZ20021839A3 (cs) 1999-12-03 2000-11-29 Rozmělněná forma (S)-2-ethoxy-3-(4-(2-(4-methansulfonyloxyfenyl)ethoxy)fenyl)propanové kyseliny
JP2001541856A JP2003515580A (ja) 1999-12-03 2000-11-29 （ｓ）−２−エトキシ−３−〔４−（２−［４−メタンスルホニルオキシフェニル］エトキシ）フェニル〕プロパン酸の微粉砕形
MXPA02005165A MXPA02005165A (es) 1999-12-03 2000-11-29 Forma pulverizada de acido [(s)- 2-etoxi -3-[4 -(2-[4- metansulfoniloxifenil) etoxi)fenil ]propanoico].
KR1020027007058A KR20020067538A (ko) 1999-12-03 2000-11-29 분쇄형(ｓ)-2-에톡시-3-[4-(2-｛4-메탄설포닐옥시페닐｝에톡시)페닐]프로판산
DK00983616T DK1237854T3 (da) 1999-12-03 2000-11-29 Pulveriseret form af (S)-2-ethoxy-3-[4-(2-(4-methan sulfonyloxyphenyl)ethoxy)phenyl]propanonsyre
PT00983616T PT1237854E (pt) 1999-12-03 2000-11-29 Forma pulverizada do acido (s)-2-etoxi-3-¬4-(2-{4- metanossulfoniloxifenil}etoxi)fenil| propanoico
SK766-2002A SK7662002A3 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2-{4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
EP00983616A EP1237854B1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
NZ518926A NZ518926A (en) 1999-12-03 2000-11-29 Comminuted form of (S)-2-ethoxy -3-[4-(2- {4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
AU20348/01A AU766036B2 (en) 1999-12-03 2000-11-29 Comminuted form of (S)-2-ethoxy -3-(4-(2- (4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
ES00983616T ES2208444T3 (es) 1999-12-03 2000-11-29 Forma pulverizada de acido (s)-2-etoxi-3-(4-(2-(4- metanosulfoniloxifenil)etoxi)fenil)propanoico.
US10/148,825 US7084177B2 (en) 1999-12-03 2000-11-29 Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid
TR2004/00003T TR200400003T4 (tr) 1999-12-03 2000-11-29 (S)-2-Ethoxy -3-4-(2-4-Methanesulfonyloxyphenyl ethoxy) propanoic asidin birleştirilmiş hali
EEP200200284A EE200200284A (et) 1999-12-03 2000-11-29 (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm
MYPI20005601A MY125099A (en) 1999-12-03 2000-11-30 Comminuted form of (s)-2-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) penyl] propanoic acid
CO00091759A CO5271736A1 (es) 1999-12-03 2000-11-30 Forma triturada
ARP000106384A AR029456A1 (es) 1999-12-03 2000-12-01 Forma triturada
ZA200203797A ZA200203797B (en) 1999-12-03 2002-05-13 Comminuted form of (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy)phenyl] propanoic acid.
IS6399A IS6399A (is) 1999-12-03 2002-05-28 Mulið form (S)-2-etoxý-3-[4-(2-{4-metansúlfonýloxýfenýl}etoxý)fenýl]própanónsýra
NO20022591A NO20022591L (no) 1999-12-03 2002-05-31 Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre
HK03101434.9A HK1049324B (zh) 1999-12-03 2003-02-26 (s)-2-乙氧基-3-[4-(2-{4-甲磺酰基氧基苯基}乙氧基)苯基]丙酸的粉碎形式

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form

Publications (1)

Publication Number Publication Date
SE9904413D0 true SE9904413D0 (sv) 1999-12-03

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form

Country Status (32)

Country Link
EP (1) EP1237854B1 (xx)
JP (1) JP2003515580A (xx)
KR (1) KR20020067538A (xx)
CN (1) CN1216859C (xx)
AR (1) AR029456A1 (xx)
AT (1) ATE251131T1 (xx)
AU (1) AU766036B2 (xx)
BR (1) BR0016135A (xx)
CA (1) CA2392029A1 (xx)
CO (1) CO5271736A1 (xx)
CZ (1) CZ20021839A3 (xx)
DE (1) DE60005710T2 (xx)
DK (1) DK1237854T3 (xx)
EE (1) EE200200284A (xx)
ES (1) ES2208444T3 (xx)
HK (1) HK1049324B (xx)
HU (1) HUP0203692A3 (xx)
IL (1) IL149516A0 (xx)
IS (1) IS6399A (xx)
MX (1) MXPA02005165A (xx)
MY (1) MY125099A (xx)
NO (1) NO20022591L (xx)
NZ (1) NZ518926A (xx)
PL (1) PL355372A1 (xx)
PT (1) PT1237854E (xx)
RU (1) RU2248966C2 (xx)
SE (1) SE9904413D0 (xx)
SK (1) SK7662002A3 (xx)
TR (1) TR200400003T4 (xx)
UA (1) UA73959C2 (xx)
WO (1) WO2001040169A1 (xx)
ZA (1) ZA200203797B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
BR9812770A (pt) 1997-10-27 2000-12-12 Reddy Research Foundation Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
MXPA00004036A (es) 1997-10-27 2006-05-24 Reddys Lab Ltd Dr Compuestos triciclicos novedosos y su uso en medicina; proceso para su preparacion y composiciones farmaceuticas que los contienen..
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
UA60386C2 (uk) 1998-10-29 2003-10-15 Reddys Laboratories Ltd Спосіб одержання похідних 3-[4-[2-(феноксазин-10-іл)метокси]феніл]пропіонової кислоти (варіанти) та проміжні сполуки для їх отримання
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
RU2480453C2 (ru) 2007-03-08 2013-04-27 Альбирео Аб Новые соединения
MX2009013354A (es) 2007-06-04 2010-07-06 Univ Ben Gurion Compuestos de triarilo y composiciones que los contienen.
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CA2928725A1 (en) 2013-11-05 2015-05-14 Esther Priel Compounds for the treatment of diabetes and disease complications arising from same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
NO20022591D0 (no) 2002-05-31
PT1237854E (pt) 2004-02-27
AU2034801A (en) 2001-06-12
HUP0203692A3 (en) 2005-05-30
DE60005710D1 (en) 2003-11-06
DK1237854T3 (da) 2004-01-12
SK7662002A3 (en) 2002-10-08
HK1049324B (zh) 2004-04-30
RU2248966C2 (ru) 2005-03-27
NZ518926A (en) 2003-11-28
MXPA02005165A (es) 2003-09-25
HUP0203692A2 (hu) 2003-03-28
EP1237854B1 (en) 2003-10-01
ATE251131T1 (de) 2003-10-15
DE60005710T2 (de) 2004-08-05
EP1237854A1 (en) 2002-09-11
TR200400003T4 (tr) 2004-02-23
AR029456A1 (es) 2003-07-02
IS6399A (is) 2002-05-28
AU766036B2 (en) 2003-10-09
IL149516A0 (en) 2002-11-10
EE200200284A (et) 2003-08-15
ZA200203797B (en) 2003-08-13
MY125099A (en) 2006-07-31
PL355372A1 (en) 2004-04-19
CN1402704A (zh) 2003-03-12
KR20020067538A (ko) 2002-08-22
UA73959C2 (en) 2005-10-17
WO2001040169A1 (en) 2001-06-07
CO5271736A1 (es) 2003-04-30
CA2392029A1 (en) 2001-06-07
ES2208444T3 (es) 2004-06-16
CN1216859C (zh) 2005-08-31
CZ20021839A3 (cs) 2002-08-14
HK1049324A1 (en) 2003-05-09
NO20022591L (no) 2002-05-31
JP2003515580A (ja) 2003-05-07
RU2002113169A (ru) 2004-01-20
BR0016135A (pt) 2002-08-20

Similar Documents

Publication Publication Date Title
SE9904413D0 (sv) Comminuted form
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
MA27702A1 (fr) Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
BR0313162A (pt) Composto, processo para preparar o mesmo, e, composição farmacêutica
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
SE9901573D0 (sv) New compounds
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
SE9904421D0 (sv) New compounds
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EA200200489A1 (ru) Новые соединения бензотиадиазина, способ их получения и содержащие их фармацевтические композиции
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
SE9904412D0 (sv) Comminuted form
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
SE9901572D0 (sv) New compounds
SE9904416D0 (sv) Crystalline form